Previously $290M-$335M. FY24 revenue consensus $292.97M. FY 2024-2025 Net Income expected to exceed $60 Million to $110 Million, respectively, increased from $55 Million and $100 Million previously. FY 2024 Adjusted EBITDA anticipated to reach $85 Million or more.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADMA:
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
- ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
- ADMA Biologics announces FDA approval of BIVIGAM in pediatric patient setting
- ADMA Biologics receives FDA approval for tenth plasma collection cent er
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
